Biocon subsidiary to Invest USD 56 Million in Syngene USA Inc for Biologics Facility Acquisition; DIIs increased their stake in last Quarter
Biocon subsidiary to Invest USD 56 Million in Syngene USA Inc for Biologics Facility Acquisition; DIIs increased their stake in last Quarter

Biocon subsidiary to Invest USD 56 Million in Syngene USA Inc for Biologics Facility Acquisition; DIIs increased their stake in last Quarter

With a PE ratio of 57.6x, the company trades at a premium compared to the industry PE of 46x. The company has ROCE of 14.7 per cent and ROE of 13.2 per cent.  

Prajwal Wakhare Article rating: 5.0

DSIJ MINDSHARE

Mkt Commentary12-Mar, 2025

Mindshare12-Mar, 2025

Penny Stocks12-Mar, 2025

Multibaggers12-Mar, 2025

Mindshare12-Mar, 2025

Knowledge

Fundamental9-Mar, 2025

Technical8-Mar, 2025

Knowledge8-Mar, 2025

Understanding the Retail Debt Market

Understanding the Retail Debt Market

Debt securities are financial instruments like bonds or loans issued by companies or governments to raise...
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR